Results 151 to 160 of about 51,615 (305)
Is the combination of Myelodysplastic syndromes and pulmonary fibrosis accidental or inevitable? [PDF]
He Y +6 more
europepmc +1 more source
Cost‐effectiveness of a hypothetical assay to evaluate stored blood quality prior to transfusion
Abstract Background and Objectives Unsuccessful red blood cell (RBC) transfusion, necessitating unscheduled repeat transfusion, is common and costly. Several technologies have been developed to assess stored blood quality, but the potential cost‐effectiveness of pretransfusion testing versus no testing to prevent unscheduled re‐transfusion is unknown ...
Melissa C. Caughey +3 more
wiley +1 more source
ABSTRACT We present a rare and diagnostically challenging case of a pancreatic neuroendocrine tumor (pNET) with intraductal growth into the main pancreatic duct (MPD), complicated by severe thrombocytopenia due to myelodysplastic syndrome. A 37‐year‐old male presented with thrombocytopenia.
Koichi Soga +9 more
wiley +1 more source
Platelet glycosylation in myelodysplastic syndromes correlates with disease severity. [PDF]
Rosenbalm KE +10 more
europepmc +1 more source
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease [PDF]
AVILIA, SIMONA +7 more
core +1 more source
What's new? Childhood cancer ranks among the leading causes of disease‐related deaths in children in high‐income countries. Established risk factors, however, account for only a small proportion of incident childhood cancers. In this report, the authors present the first long‐term assessment of temporal trends in childhood cancer incidence rates in ...
Friederike Erdmann +8 more
wiley +1 more source
Myelodysplastic syndromes: A primary care perspective. [PDF]
Naidoo K, Parasnath S.
europepmc +1 more source
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman +15 more
wiley +1 more source
Impact of inflammatory cytokine polymorphisms on the progression of myelodysplastic syndromes. [PDF]
Gotoh N +17 more
europepmc +1 more source
Improved survival after acute graft-versus-host disease diagnosis in the modern era [PDF]
et al.,, Hayashi, Robert J, Vig, Ravi
core +1 more source

